Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria. The company owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-resistant modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. Its product candidates also comprise REST-ON, which is in Phase III clinical trial for the treatment of daytime sleepiness and cataplexy in patients suffering from narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. The company was founded in 1990 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone636-449-1830
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$103.27 million
Profitability
Miscellaneous
Employees169
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Avadel Pharmaceuticals (NASDAQ:AVDL) Frequently Asked Questions
What is Avadel Pharmaceuticals' stock symbol?
Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL."
How will Avadel Pharmaceuticals' stock buyback program work?
Avadel Pharmaceuticals announced that its Board of Directors has initiated a share repurchase plan on Wednesday, March 28th 2018, which permits the company to repurchase $7,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.7% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.
How were Avadel Pharmaceuticals' earnings last quarter?
Avadel Pharmaceuticals PLC (NASDAQ:AVDL) released its quarterly earnings data on Friday, March, 15th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.06. The company earned $20.92 million during the quarter. Avadel Pharmaceuticals had a negative return on equity of 126.79% and a negative net margin of 92.29%. View Avadel Pharmaceuticals' Earnings History.
When is Avadel Pharmaceuticals' next earnings date?
What price target have analysts set for AVDL?
4 brokerages have issued 1 year price targets for Avadel Pharmaceuticals' stock. Their predictions range from $2.00 to $10.00. On average, they expect Avadel Pharmaceuticals' stock price to reach $6.00 in the next year. This suggests a possible upside of 426.3% from the stock's current price. View Analyst Price Targets for Avadel Pharmaceuticals.
What is the consensus analysts' recommendation for Avadel Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Avadel Pharmaceuticals.
Has Avadel Pharmaceuticals been receiving favorable news coverage?
News headlines about AVDL stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Avadel Pharmaceuticals earned a coverage optimism score of 1.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Avadel Pharmaceuticals' key competitors?
Some companies that are related to Avadel Pharmaceuticals include Tyme Technologies (TYME), BioXcel Therapeutics (BTAI), BELLUS Health (BLUSF), Aquestive Therapeutics (AQST), Northwest Biotherapeutics (NWBO), Humanigen (HGEN), AVEO Pharmaceuticals (AVEO), Chiasma (CHMA), ASLAN PHARMACEU/ADR (ASLN), CytoDyn (CYDY), Axovant Sciences (AXON), Chimerix (CMRX), Bellicum Pharmaceuticals (BLCM), Trevena (TRVN) and Eton Pharmaceuticals (ETON).
What other stocks do shareholders of Avadel Pharmaceuticals own?
Who are Avadel Pharmaceuticals' key executives?
Avadel Pharmaceuticals' management team includes the folowing people:
- Mr. Michael F. Kanan, Sr. VP & CFO (Age 56)
- Mr. Phillandas T. Thompson, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Gregory J. Divis, VP of Corp. and Bus. Devel. (Age 54)
- Dr. David Monteith, VP of R&D (Age 55)
- Mr. Gregory J. Divis Jr., Interim CEO (Age 52)
Who are Avadel Pharmaceuticals' major shareholders?
Avadel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.10%). Company insiders that own Avadel Pharmaceuticals stock include Craig R Stapleton, Greg J Divis, Guillaume Cerutti, Healthcare Master Fun Broadfin, James E Flynn, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Institutional Ownership Trends for Avadel Pharmaceuticals.
Which institutional investors are buying Avadel Pharmaceuticals stock?
AVDL stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Avadel Pharmaceuticals stock in the last two years include Craig R Stapleton, Greg J Divis, Michael S Anderson, Peter J Thornton, Phillandas T Thompson and Sandra L Hatten. View Insider Buying and Selling for Avadel Pharmaceuticals.
How do I buy shares of Avadel Pharmaceuticals?
Shares of AVDL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Avadel Pharmaceuticals' stock price today?
One share of AVDL stock can currently be purchased for approximately $1.14.
How big of a company is Avadel Pharmaceuticals?
Avadel Pharmaceuticals has a market capitalization of $42.19 million and generates $103.27 million in revenue each year. The company earns $-95,300,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Avadel Pharmaceuticals employs 169 workers across the globe.
What is Avadel Pharmaceuticals' official website?
How can I contact Avadel Pharmaceuticals?
Avadel Pharmaceuticals' mailing address is BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK BALLYCOOLIN, DUBLIN L2, 63005. The company can be reached via phone at 636-449-1830 or via email at [email protected]
MarketBeat Community Rating for Avadel Pharmaceuticals (NASDAQ AVDL)
MarketBeat's community ratings are surveys of what our community members think about Avadel Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVDL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVDL will underperform the S&P 500 over the long term. You may vote once every thirty days.
